2 results
Approved WMOWill not start
Part BPrimary:• To determine the anti-tumor activity of NM21 1480 according to RECIST 1.1• To assess the safety and tolerability of NM21 1480 in patients with selected advanced cancers treated at or around the recommended Phase 2 dose (RP2D)• To…
Approved WMORecruiting
Primary objective: To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior STEMI undergoing pPCI.Secondary objective:To assess the effect of FDY-5301 on other clinical outcomes such as all-…